BMS's Blockbuster Reblozyl Fails to Meet Primary Endpoint in Phase 3 Trial for Myelofibrosis-Associated Anemia

2025Year7Month18Day, Bristol-Myers Squibb (Bristol Myers Squibb, AbbreviationBMS) announced that its best-selling anemia drugReblozylIn patients with myelofibrosisIIIFailed to reach the primary endpoint in the Phase III clinical trial. This news has drawn industry attention to the field of treatment for anemia related to myelofibrosis, and also brought this drug, which has been on the market for many years, back into the spotlight.

ReblozylThis time, the launch of3PeriodINDEPENDENCEThe trial's main purpose is to evaluate whether the drug can reduce the need for red blood cell transfusions in patients with myelofibrosis. The primary endpoint of the trial was set as: after the start of treatment.24Within the week, continuously12Zhou achieved red blood cell transfusion independence. However,BMSIn the press release on Friday, it was stated that the drug failed to reach this primary endpoint, did not significantly reduce patients' need for red blood cell transfusions, and no specific data was released.

However,BMSAt the same time, it was pointed out that acceptanceReblozylPatients treated have achieved infusion independence“Numerical and Clinically Meaningful Improvement”. In addition, multiple items in the trial“Key Secondary Endpoints”ShowedReblozylFavorable clinical significance benefits, including reduced infusion burden, and at least consecutive12Zhou maintained infusion independence while hemoglobin levels improved. However, the company did not specify whether these secondary endpoints reached statistical significance.

BMO Capital MarketsThe analyst mentioned in the report to investors that the results of this trial“Highlights the current lack of effective treatment options for anemia associated with myelofibrosis.”, while pointing out“Due to the lack of quantified data on infusion independence, it is difficult to clearly assess the improvement in serological indicators and the functional enhancement of infusion independence.ReblozylThe True Impact of Anemia”。

Although the trial did not meet its primary endpoint,BMSCorrectReblozylClinical Activity in Anemia Associated with Myelofibrosis Remains“Inspire”Attitude.BMSThe head of hematology, oncology, and cell therapy development believes that the trial results are“Promising”, with a focus on receivingReblozylTreating Patients“Clinically Relevant Improvement”. She stated,“These results overall support its potential to address unmet patient needs.——These patients have virtually no other treatment options.”

In terms of safety, the safety data of this drug in the current trial is consistent with previous trials, and no new safety issues have emerged.

Based on the existing results,BMSPlan to collaborate with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Communication, explore submissionReblozylPossibility of Marketing Application for Anemia Associated with Myelofibrosis.

ReblozylIt is a recombinant fusion protein administered via subcutaneous injection, and its mechanism of action is to improve the number and quality of mature red blood cells. This drug was2019First obtained in the yearFDAApproved for adults requiring regular blood transfusionsβAnemia treatment in patients with thalassemia. Subsequently, its indications have been continuously expanded and it has been approved for the treatment of anemia in patients with very low to intermediate-risk myelodysplastic syndrome or myeloproliferative neoplasms.

AsBMSOne of the top-selling assets,ReblozylThe market performance is very impressive.2024In that year, the drug's sales surged year-on-year.76%, reaching17.7Billion US dollars;2025In the first quarter of the year, sales were4.78Billion US dollars, increased compared to the same period last year35%, continuing to maintain a strong growth momentum.

This incident highlights the unique challenges in the development of drugs for rare diseases or niche indications. As a complex and difficult condition, anemia associated with myelofibrosis suffers from a lack of effective treatment options. This has led regulatory agencies to potentially adopt a more flexible approach to drug evaluation: focusing not only on statistical significance but also on practical clinical benefits.

At present, the industry is paying close attention. BMS The results of communication with regulatory authorities, andINDEPENDENCEThe release of the complete trial data will further reveal these insights.ReblozylThe True Value in the Treatment of Anemia Associated with Myelofibrosis.

Reference:biospace

●Breaking! An Astellas Executive Sentenced to Three and a Half Years for Espionage

●2025, A Major Reshuffle in Pharmaceutical Companies' Control!

●$500 Million! China Biologic Products Acquires Limin Pharmaceuticals